Peptipedia
CognitiveNot FDA ApprovedClinical Trials

Semax

Also known as SEMAX, Heptapeptide SEMAX

Synthetic peptide derived from ACTH (4-10) fragment with added Pro-Gly-Pro sequence. Used clinically in Russia for stroke, traumatic brain injury, and cognitive disorders.

Approved in Russia - Not FDA approved
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

200-600 mcg intranasal daily

Frequency

1-3x daily

Duration

10-30 days typical

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 200-600 mcg intranasal daily via Intranasal spray (most common), 1-3x daily. Dose range: 200-600 mcg per dose. Duration: 10-30 days typical.

Timing & Administration

Administer via Intranasal spray (most common). Frequency: 1-3x daily.

Mechanism of Action

Increases BDNF and NGF expression, modulates dopamine and serotonin systems, and has anti-inflammatory effects in the brain.

Research Summary

Evidence level: clinical trials. Clinical status: Approved in Russia - Not FDA approved.

Side Effects & Safety

Important Warnings

  • Caution with SSRIs and MAOIs
Nasal irritation
headache
insomnia
increased anxiety (paradoxical)
nausea

References

No references available.

Related Peptides

Browse all →
SelankCognitive

A synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects.

View profile
CerebrolysinCognitive

A neuropeptide mixture derived from porcine brain tissue, indicated for neurological conditions including stroke recovery, cognitive decline, and traumatic brain injury.

View profile
DihexaCognitive

A potent cognitive-enhancing peptide derived from angiotensin IV. Reported to be 10 million times more potent than BDNF at promoting synaptogenesis.

View profile